Clinical Trial Update: Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing standard-dose bevacizumab to low-dose bevacizumab plus lomustine in recurrent glioblastoma multiforme (GBM); study completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Lomustine (Lomustine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Brain Cancer, Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2020-03-17